Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 /, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a ...
Taiwan News46m
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival (“DFS”) expected in H1 2025; positive results could support rapid advancement into Phase 3 ...